BioSapien, a biotechnology company based in Abu Dhabi, has raised US$1.8 million in a seed funding round led by SOSV.

Other investors include Hikma Ventures, Microventures, Infinity Capital Ventures, JPIN VCATS, and Side Door Ventures.

The funds will support the development of BioSapien’s MediChip™, a 3D-printed biodegradable mesh designed to deliver cancer drugs directly to tumors.

Founded in 2018, BioSapien has gained recognition in biotech competitions.

The company continues to advance its clinical pipeline with support from strategic partners and investors. This platform aims to reduce side effects typically associated with systemic chemotherapy.

Additionally, BioSapien received a US$256,000 grant from the National Science Foundation to accelerate MediChip’s development.

🔗 Source: BioSapien

🧠 Food for thought

1️⃣ Localized drug delivery tackles a fundamental challenge in cancer treatment

BioSapien’s MediChip joins an emerging field of localized drug delivery systems addressing a critical limitation of traditional chemotherapy: systemic toxicity.

Despite chemotherapy’s effectiveness, its distribution throughout the body leads to serious side effects that significantly impact patient quality of life and often limit dosing.

Over 2 million new cancer cases were diagnosed in the U.S. in 2022, with 600,000 deaths, highlighting the urgent need for more effective treatment approaches 1.

The company’s focus on pancreatic cancer is particularly strategic, as this aggressive cancer has historically poor outcomes and limited treatment options for its approximately 57,000 new cases annually in the U.S.

Localized delivery systems like polymeric wafers, scaffolds, and hydrogels have shown promise by releasing drugs directly at tumor sites, which can potentially reduce systemic exposure while maintaining therapeutic efficacy 1.

BioSapien’s biodegradable mesh approach represents a specialized application of this concept, targeting the significant unmet need in stage III gastrointestinal cancers where surgical intervention provides an opportunity for direct placement.

2️⃣ Technical challenges of effective drug delivery in the GI tract